Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) CEO Rob Fia tells Proactive it has submitted follow-up answers and reformatted data to the FDA for the company's Emergency Use Authorization (EUA) application for its AcuVid COVID-19 Rapid Antigen Saliva Test. The Toronto-based company said its executive and product development teams have been working with FDA officials to clarify answers to some of the EUA application questions, as well as provided some reformatting of data to better meet the application template requirements.
Therma Bright provides update on FDA application for its AcuVid COVID-19 rapid antigen saliva test
